ReviewIntestinal research2024
Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease.
Review in Intestinal research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06845527 (Characteristics and Outcomes of Outpatients Referred to an Gut Microbiota Clinic), which is not on this map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Characteristics and Outcomes of Outpatients Referred to an Gut Microbiota Clinic
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Butyrate-Producing Bacteria as a Keystone Species of the Gut Microbiome: A Systemic Review of Dietary Impact on Gut-Brain and Host Health.International journal of molecular sciences · 2026Pooled it
- Healing from Within: How Gut Microbiota Predicts IBD Treatment Success-A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Effects of stoma discharge reinfusion on low anterior resection syndrome and the gut microbiota following sphincter-preserving surgery for middle and low rectal cancer: a randomized clinical trial.Updates in surgery · 2026Trial
- Poricoic acid A administered during DSS exposure attenuates acute colitis in mice and is accompanied by barrier-associated changes and endpoint fecal microbiota shifts.Journal of natural medicines · 2026Article
- A Multi-Target Approach to Colitis: Ergothioneine Promotes Recovery by Restoring the Intestinal Barrier, Reducing Inflammation, and Remodeling the Microbiota.Food science & nutrition · 2026Article
- Fecal microbiota fermenting simple organic carbon substrates in vitro as microbial factories capable of distinguishing Crohn's disease from healthy states.Microbial cell factories · 2026Article
- A novel multi-epitope mRNA vaccine against Escherichia coli using an in silico reverse vaccinology approach.Journal of applied genetics · 2026Article
- Antibiotic Class-Specific Effects on Inflammatory Bowel Disease: Microbiome Disruption, Risk, and Recovery.International journal of molecular sciences · 2026Review
- Proactive therapeutic drug monitoring of infliximab leads to treatment durability in paediatric Crohn's disease: A single-centre Australian experience.JPGN reports · 2026Article
- Specificity vs. Synergy Between Single-Strain and Multi-Strain Probiotics for Ulcerative Colitis Treatment: A Review of the Literature.Biomedicines · 2026Review
- Therapeutic Potential and Functional Mechanisms of Probiotics as Prospective anti-inflammatory Agents.Probiotics and antimicrobial proteins · 2026Review
- CXCL5 is associated with neutrophil-driven intestinal inflammation and IL-17-associated epithelial signaling in inflammatory bowel disease.Scientific reports · 2026Article
- Integrated multi-omics profiling of gut microbiome and metabolome in ulcerative colitis insights from the Iranian population.iScience · 2026Article
- Deciphering the mitochondria-gut microbiota axis in irritable bowel syndrome: pathogenic insights and therapeutic frontiers.Journal of translational medicine · 2026Review
- The epidemiology of inflammatory bowel disease: exploring the impacts of environmental factors.The Korean journal of internal medicine · 2026Review
- Maternal gut microbial legacy shapes intestinal health and susceptibility of offspring to colitis.NPJ biofilms and microbiomes · 2026Article
- Gut Microbiota Alterations and Dysbiosis Patterns in Pediatric Inflammatory Bowel Disease: Clinical Correlations and Therapeutic Impact.Journal of clinical medicine · 2026Article
- Relationship between the appendix and ulcerative colitis: A new discovery.World journal of gastrointestinal endoscopy · 2026Review
- Host-microbe interaction networks revealed through gut microbiota and microRNA correlation analysis in mouse models of chronic colitis and colitis-associated cancer.Journal of translational medicine · 2026Article
- Molecular and morphological characteristics ofFrontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Inflammatory bowel disease (IBD) is a multifactorial disease, which is thought to be an interplay between genetic, environment, microbiota, and immune-mediated factors. Dysbiosis in the gut microbial composition, caused by antibiotics and diet, is closely related to the initiation and progression of IBD. Differences in gut microbiota composition between IBD patients and healthy individuals have been found, with reduced biodiversity of commensal microbes and colonization of opportunistic microbes in IBD patients. Gut microbiota can, therefore, potentially be used for diagnosing and prognosticating IBD, and predicting its treatment response. Currently, there are no curative therapies for IBD. Microbiota-based interventions, including probiotics, prebiotics, synbiotics, and fecal microbiota transplantation, have been recognized as promising therapeutic strategies. Clinical studies and studies done in animal models have provided sufficient evidence that microbiota-based interventions may improve inflammation, the remission rate, and microscopic aspects of IBD. Further studies are required to better understand the mechanisms of action of such interventions. This will help in enhancing their effectiveness and developing personalized therapies. The present review summarizes the relationship between gut microbiota and IBD immunopathogenesis. It also discusses the use of gut microbiota as a noninvasive biomarker and potential therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.